scholarly journals THE EFFECT OF DIACEREIN AND MELOXICAM COMBINATION VERSUS MELOXICAM ALONE ON PHYSICAL FUNCTION IN PATIENTS WITH KNEE OSTEOARTHRITIS

2018 ◽  
Vol 11 (10) ◽  
pp. 325
Author(s):  
Ni Made Oka Dwicandra ◽  
Made Krisna Adi Jaya
Keyword(s):  
Combination Therapy ◽  
Knee Osteoarthritis ◽  
Physical Function ◽  
Therapy Group ◽  
Controlled Trial ◽  
Area Under The Curve ◽  
Combination Group ◽  
Function Score ◽  
Knee Oa ◽  
Physical Function Score

Objective: More than 50% of patients with knee osteoarthritis (OA) had an inadequate pain relief in its management. Combination therapy could be the solution to this problem. The aim of this study was to compare the efficacy of combination therapy of diacerein and meloxicam with meloxicam alone in the patient with knee OA.Methods: A total of 64 knee OA patients were recruited from Rumah Sakit Umum Daerah Dr. Mohammad Soewandhie Surabaya. They were allocated to combination group and single therapy group using randomized controlled trial design. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) physical function questionnaire were assessed in weeks 0–4th. The difference between pre- and post-treatment score and area under the curve (AUC) of WOMAC score were calculated.Results: Combination therapy and single therapy had significant clinical effect with the downregulated score of WOMAC physical function after 4th week (p<0.05). However, there were no differences in AUC of WOMAC physical function score between combination and single therapy.Conclusion: Patient with knee OA could gain beneficial efficacies from combination therapy of diacerein and meloxicam. Studies of longer follow-up time to get the differences in AUC of WOMAC physical function score are needed.

scholarly journals Effects of Variable Frequencies of Combined Proprioceptive and Kinesthesia, Balance and Agility Exercise Program in Adults With Knee Osteoarthritis: a Study Protocol for Randomized Controlled Trial

2020 ◽  
Author(s):  
Aysha I. Adhama ◽  
Mukadas O. Akindele ◽  
Aminu A. Ibrahim
Keyword(s):  
Knee Osteoarthritis ◽  
Conventional Therapy ◽  
Therapy Group ◽  
Controlled Trial ◽  
Exercise Program ◽  
Optimal Dosage ◽  
Combined Effects ◽  
Older Individuals ◽  
Post Intervention ◽  
Knee Oa

Abstract Background:Knee osteoarthritis (OA) is a common painful and disabling condition that affects older individuals. Proprioceptive (PR) and kinesthesia, balance and agility (KBA) exercises are two neuromuscular training reported to be beneficial for individuals with knee OA. However, their combined effects have not been systematically evaluated. Moreover, the most optimal dosage of knee OA exercise-based programremains unclear. The aim of this study is to determine the combined effects of PR and KBA exercise program with different frequency of treatment sessions(i.e. twice weekly or thrice weekly) in adults with knee OA.Methods:A single (assessor) blind, three-arm parallel, multi-centerrandomized controlled trial will be conducted. Eighty-four adults with knee OA will be recruited from four tertiary hospitals in Northwestern Nigeria and randomly assigned into one of three intervention groups; group 1 (control or conventional physiotherapy; n = 28), group 2 (two sessions per week of combined PR and KBA exercise; n = 28), and group 3 (three sessions per week of combined PR and KBA exercise, n = 28). Participants in the conventional therapy group will receive two sessions of brief patient education, and 16 sessions of ultrasound therapy, and stretching, strengthening and aerobic exercise for 8 weeks. Participants in the two experimental groups will be treated for 8 weeks and will also receive the same conventional therapy. All groups will be assessed pre-intervention, immediately post-intervention and at 3-month, 4-month and 6-month post-randomization. The primary outcomes will be physical function and quality of life while the secondary outcomes will be pain intensity, knee stability and proprioception.Discussion:Findings of this study may provide evidence of effectiveness of combined PR and KBA exercise program for knee OA, which may serve as a basis for recommending the use of such multimodal exercise approachfor individuals with knee OA. The study may also provide evidence for the ideal number of sessions of knee OA exercise-based programsto achieve the highest effectiveness.Trial registration:Pan African Clinical Trials Registry, (PACTR201810713260138), Registered on 28 November 2017.

scholarly journals Aquatic Physical Therapy for Hip and Knee Osteoarthritis: Results of a Single-Blind Randomized Controlled Trial

2007 ◽  
Vol 87 (1) ◽  
pp. 32-43 ◽  
Author(s):  
Rana S Hinman ◽  
Sophie E Heywood ◽  
Anthony R Day
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Physical Therapy ◽  
Muscle Strength ◽  
Knee Osteoarthritis ◽  
Physical Function ◽  
Controlled Trial ◽  
Knee Oa ◽  
Randomized Controlled

Background and Purpose Aquatic physical therapy is frequently used in the management of patients with hip and knee osteoarthritis (OA), yet there is little research establishing its efficacy for this population. The purpose of this study was to evaluate the effects of aquatic physical therapy on hip or knee OA. Subjects A total of 71 volunteers with symptomatic hip OA or knee OA participated in this study. Methods The study was designed as a randomized controlled trial in which participants randomly received 6 weeks of aquatic physical therapy or no aquatic physical therapy. Outcome measures included pain, physical function, physical activity levels, quality of life, and muscle strength. Results The intervention resulted in less pain and joint stiffness and greater physical function, quality of life, and hip muscle strength. Totals of 72% and 75% of participants reported improvements in pain and function, respectively, compared with only 17% (each) of control participants. Benefits were maintained 6 weeks after the completion of physical therapy, with 84% of participants continuing independently. Discussion and Conclusion Compared with no intervention, a 6-week program of aquatic physical therapy resulted in significantly less pain and improved physical function, strength, and quality of life. It is unclear whether the benefits were attributable to intervention effects or a placebo response.

scholarly journals Therapeutic effects of turmeric or curcumin extract on pain and function for individuals with knee osteoarthritis: a systematic review

2021 ◽  
Vol 7 (1) ◽  
pp. e000935
Author(s):  
Kristopher Paultre ◽  
William Cade ◽  
Daniel Hernandez ◽  
John Reynolds ◽  
Dylan Greif ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Physical Function ◽  
Therapy Group ◽  
Cochrane Review ◽  
Final Analysis ◽  
Cochrane Collaboration ◽  
Allocation Concealment ◽  
Therapeutic Effects ◽  
Knee Oa ◽  
And Function

PurposeTo determine whether supplementation with turmeric or curcumin extract effects pain and physical function in individuals with knee osteoarthritis (OA). Second, we investigated the therapeutic response (pain and function) of turmeric compared with non-steroidal anti-inflammatory drugs (NSAIDs).MethodsA search was conducted in MEDLINE, Embase, CINAHL and Cochrane Review. Inclusion criteria included randomised controlled trials reporting pain and physical function in humans with knee OA comparing turmeric therapy with NSAIDs or no therapy. Two reviewers screened 5273 abstracts. Risk of bias and quality were assessed via Cochrane Collaboration tool and CONSORT (Consolidated Standards of Reporting Trials) 2010, respectively.ResultsTen studies were included in the final analysis. Eight had high methodological quality and two were categorised as good with a mean CONSORT quality score of 21.1. Nine studies had adequate sequence generation and six had adequate allocation concealment. Participants and outcome assessors were blinded in eight studies. Three of the studies compared turmeric therapy to NSAIDs. All 10 studies showed improvement in pain and function from baseline with turmeric therapy (p≤0.05). In three studies comparing turmeric to NSAIDs, there were no differences in outcome scores (p>0.05). In all studies there were no significant adverse events in the turmeric therapy group.ConclusionCompared with placebo, there appears to be a benefit of turmeric on knee OA pain and function. Based on a small number of studies the effects are similar to that of NSAIDs. Variables such as optimal dosing, frequency and formulation remain unclear at this time.

scholarly journals Efficacy of Leg Swing Versus Quadriceps Strengthening Exercise Among Patients With Knee Osteoarthritis: Study Protocol for a Randomized Controlled Trial

2021 ◽  
Author(s):  
Ruiyang Li ◽  
Pingping Sun ◽  
Yu Zhan ◽  
Xuetao Xie ◽  
Weibing Yan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Surgical Treatment ◽  
Knee Osteoarthritis ◽  
Physical Function ◽  
Knee Pain ◽  
Controlled Trial ◽  
Knee Oa ◽  
Randomized Controlled ◽  
Strengthening Exercise ◽  
Non Surgical Treatment

Abstract Background Knee osteoarthritis (OA) is a leading cause of global disability. According to guidelines, thus far, exercise is the most recommended and important non-surgical treatment for knee OA. However, the best type of exercise for this condition remains unclear. There is evidence showing that traditional Chinese exercises may be more effective. Therefore, the current prospective, two-armed, single-center randomized controlled trial (RCT) aimed to identify an effective physiotherapy for knee OA. Methods/design: In total, 128 patients with painful knee OA will be recruited from the orthopaedic outpatient department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. To compare the therapeutic effect of two different home-based exercise programs, the participants will be randomly assigned into the experimental group (leg swing exercise) or the control group (quadriceps strengthening exercise). Each participant in both groups will be required to attend five individual sessions with a physiotherapist who will teach the exercise program and monitor progress. Participants will be instructed to perform the exercises at home every day for 12 weeks. Clinical outcomes will be assessed at baseline and 12 and 24 weeks after starting the intervention. The primary outcomes are average overall knee pain and physical function in daily life. The secondary outcomes include other measures of knee pain, physical function, patient-perceived satisfactory improvement, health-related quality of life, physical activity and performance, muscle strength of the lower limb, and adherence. Discussion This study will provide more evidence on the effects of traditional Chinese exercise on improving physical function and relieving joint pain among patients with knee OA. If proven effective, leg swing exercise can be used as a non-surgical treatment for knee OA in the future. Trial registration: Chinese Clinical Trial Registry reference: ChiCTR2000039005, registered 13/10/2020. http://www.chictr.org.cn/showproj.aspx?proj=62497

scholarly journals COMPARISON OF PAIN SCORE IN OSTEOARTHRITIS PATIENTS TREATED WITH A COMBINATION OF DIACEREIN AND MELOXICAM AND MELOXICAM ALONE

2017 ◽  
Vol 9 (6) ◽  
pp. 69
Author(s):  
Ni Made Oka Dwicandra ◽  
Antonious Adji Prayitno Setiadi
Keyword(s):  
Randomized Controlled Trial ◽  
Articular Cartilage ◽  
Combination Therapy ◽  
Pain Intensity ◽  
Pain Score ◽  
Controlled Trial ◽  
Area Under The Curve ◽  
Randomized Controlled ◽  
Pain Outcome ◽  
Inflammatory Drugs

Objective: Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. In managing OA, inadequate pain relief (IPR) often occurs, particularly with a single non steroidal anti-inflammatory drugs (NSAIDs) therapy. In this research, pain outcome of OA patients treated with a combination of diacerein and meloxicam vs meloxicam alone was evaluated.Methods: This research was conducted at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya by using randomized controlled trial (RCT) design. Pain outcome was evaluated by pain intensity and area under the curve (AUC) of pain score in week 0-4th.Results: There were a significantly different (p<0.05) in pain intensity seen in 3rd and 4th weeks after treated with a combination of diacerein and meloxicam, and with meloxicam only. However, there were no different in AUC pain score between combination and single therapy.Conclusion: Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination therapy of diacerein and meloxicam occurred at 3rd weeks. The prolong study in order to get the differences in AUC pain score are needed.

scholarly journals Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e024065 ◽  
Author(s):  
Henrik Gudbergsen ◽  
Marius Henriksen ◽  
Eva Ejlersen Wæhrens ◽  
Anders Overgaard ◽  
Henning Bliddal ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Knee Osteoarthritis ◽  
Controlled Trial ◽  
Single Centre ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Knee Oa ◽  
Parallel Group ◽  
Pain Subscale

IntroductionWith an increasing prevalence of citizens of older age and with overweight, the health issues related to knee osteoarthritis (OA) will intensify. Weight loss is considered a primary management strategy in patients with concomitant overweight and knee OA. However, there are no widely available and feasible methods to sustain weight loss in patients with overweight and knee OA. The present protocol describes a randomised controlled trial evaluating the efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide in a 3 mg/day dosing in patients with overweight and knee OA.Methods and analysis150 volunteer adult patients with overweight or obesity and knee OA will participate in a randomised, double-blind, placebo-controlled, parallel-group and single-centre trial. The participants will partake in a run-in diet intervention phase (week −8 to 0) including a low calorie diet and dietetic counselling. At week 0, patients will be randomised to either liraglutide 3 mg/day or liraglutide placebo 3 mg/day for 52 weeks as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. The co-primary outcomes are changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to week 52.Ethics and disseminationThe trial has been approved by the regional ethics committee in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospitals) will oversee the trial. The results will be presented at international scientific meetings and through publications in peer-reviewed journals.Trial registration numbers2015-005163-16,NCT02905864, U1111-1171-4970Based on protocol versionV.6; 30 January 2017, 15:30 hours

scholarly journals The Comparison of Hypomethylating Agents (HMA) Monotherapy with HMA Combined with Intensive Chemotherapy for Intermediate / High-Risk MDS or AML

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3903-3903
Author(s):  
Jiang Ji ◽  
Zhao Wang ◽  
Bing Han
Keyword(s):  
High Risk ◽  
Combination Therapy ◽  
Death Rate ◽  
Therapy Group ◽  
Meta Analysis ◽  
Combination Group ◽  
Combination Therapy Group ◽  
Hypomethylating Agents ◽  
Monotherapy Group ◽  
Significant Difference

Introduction: Hypomethylating agents (HMA) azacitidine and decitabine were the first-line therapy for intermediate/ higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients unsuitable for hematopoietic cell transplantation (HSCT). HMA combined with chemotherapy was recently used to achieve for a better outcome. However, few studies were carried out to compare the HMA monotherapy to the HMA and chemotherapy combination therapy. This meta-analysis aimed to compare the efficacy, survival benefit and safety of HMA monotherapy and combination therapy (with chemotherapy) in patients with intermediate/high-risk MDS or AML. Methods: Related articles published between January 2009 and April 2019 were selected and patients were separated as monotherapy group and combination group for meta-analysis. To further eliminate the potential influence of differences in patients' baseline characteristic between the two groups, subgroups with similar patients' baseline characteristics were selected for further analysis. Complete response (CR) rate, overall response (ORR) rate, 1-year overall survival (OS) rate, 1-month death rate and the proportion of adverse event (AE) were pooled and compared. Results: 13 RCT or cohort studies with 997 patients (790 in monotherapy group, 207 in HMA combination group) were selected for meta-analysis. For the pooled data, there was no significant difference in sex and cytogenetic risk between the 2 groups, but the age of combination therapy group was significantly younger than that of the monotherapy group (61.3±13.2 year-old vs 67.7±10.2 year-old, p=0.000). The CR and ORR rate were significantly higher in combination therapy group (53% vs 17%, p=0.000 for CR and 67% vs 44%, p=0.000 for ORR). However, the 1-year OS (56% for combination therapy vs 51% for HMA monotherapy group, p=0.282) and 1-month death rate (5% for combination therapy vs 4% for HMA monotherapy group, p=0.965) were similar between the two groups. The incidence of CTCAE grade 3-4 infection and bleeding were significantly higher (infection: 50% for combination therapy vs 25.7% for monotherapy group, p=0.003; bleeding: 27.5%% for combination therapy vs 7.8% for monotherapy group, p=0.004) in combination group. In subgroup analysis, 117 and 179 patients were included in combination group and HMA monotherapy group, respectively. There was no significant difference in age (69.5±4.6 vs 69.0±6.8 years old, p=0.451) and proportion of favorable/intermediate cytogenetic risk (62% vs 71%, p=0.114) between the two groups, but a significantly lower proportion of male was found in combination therapy group (57% vs 74%, p=0.003). Although combination group had a higher CR rate (49% vs 17%, p=0.000), it had similar ORR rate (58% vs 49%, p=0.140) to monotherapy group. Meanwhile, combination therapy came with higher 1-month death rate (12% vs 3%, p=0.008) and lower 1-year OS (54% vs 68%, p=0.013) compared with monotherapy group. Conclusions: HMA combined with chemotherapy could increase CR rate in all patients and ORR rate in younger patients, but could not improve OS. For patients with similar older age, combination therapy could result in higher 1-month death rate and less 1-year OS. Disclosures No relevant conflicts of interest to declare.

PROMIS Physical Function Score Strongly Correlates With Legacy Outcome Measures in Minimally Invasive Lumbar Microdiscectomy

Spine ◽  
2019 ◽  
Vol 44 (6) ◽  
pp. 442-446 ◽  
Author(s):  
Benjamin Khechen ◽  
Brittany E. Haws ◽  
Dil V. Patel ◽  
Mundeep S. Bawa ◽  
Islam M. Elboghdady ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Physical Function ◽  
Outcome Measures ◽  
Function Score ◽  
Lumbar Microdiscectomy ◽  
Physical Function Score

scholarly journals Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial

BMJ Open ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. e022448 ◽  
Author(s):  
Nam Hoon Kim ◽  
Soo Lim ◽  
Soo Heon Kwak ◽  
Min Kyong Moon ◽  
Jun Sung Moon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Combination Therapy ◽  
Therapy Group ◽  
Controlled Trial ◽  
Triple Combination ◽  
Open Label ◽  
Triple Combination Therapy ◽  
Drug Naïve

IntroductionPatients with type 2 diabetes are at risk of microvascular and macrovascular complications. Intensive glycaemic control, especially in patients with short duration of diabetes, is the mainstay of management of type 2 diabetes to lower the risk of complications. However, despite the improvement in the understanding of the pathophysiology of type 2 diabetes and development of novel glucose-lowering agents, long-term durable glycaemic control remains a difficult goal to achieve. Several challenging clinical trials proved that an early combination therapy with a variety of glucose-lowering agents had a more favourable effect than conventional stepwise therapy in terms of glycaemic control. We aim to evaluate the efficacy and tolerability of a novel, initial triple combination therapy with metformin, sodium glucose cotransporter 2 inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor (saxagliptin) compared with conventional stepwise add-on therapy in drug-naïve patients with recent-onset type 2 diabetes.Methods and analysisThis study is a multicentre, prospective, randomised, open-label, parallel group, comparator-controlled trial. A total of 104 eligible participants will be randomised to either the initial combination therapy group or the conventional stepwise add-on therapy group for 104 weeks. The primary endpoint is the proportion of patients who achieved haemoglobin A1c level<6.5% without hypoglycaemia, weight gain or discontinuation due to adverse events at 104 weeks. This trial will determine whether a novel triple combination therapy with metformin, dapagliflozin and saxagliptin has a beneficial effect on durable glycaemic control compared with conventional therapy in drug-naïve patients with type 2 diabetes.Ethics and disseminationThis study protocol was approved by the local institutional review boards and independent ethics committees over the recruitment sites. Results of this study will be disseminated in scientific journals and scientific conferences.Trial registration numberNCT02946632; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document